Amgen, colorectal cancer
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...
GlobalData on MSN5d
JP Morgan 2025: reduced dosing and expanded manufacturing paving way for Amgen’s obesity entranceAmgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...
Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...
Amgen (AMGN) announced that the U.S. FDA has approved Lumakras in combination with Vectibix for the treatment of adult patients with KRAS ...
Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...
High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...
Zacks.com on MSN1d
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth KnowingAmgen (AMGN) closed the most recent trading day at $272.11, moving +0.99% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1% for the day. Meanwhile, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback